Development, validation and clinical use of a LC-MS/MS method for the simultaneous determination of the nine main antituberculosis drugs in human plasma.

Fage, David; Brilleman, Reda; Deprez, Guillaume; Payen, Marie-Christine; Cotton, Frédéric

Fage, David; Brilleman, Reda; Deprez, Guillaume; Payen, Marie-Christine; Cotton, Frédéric.

Afiliação

Fage D; Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium. Electronic address: david.fage@lhub-ulb.be.
Brilleman R; Université Libre de Bruxelles, Brussels, Belgium.
Deprez G; Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.
Payen MC; Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium.
Cotton F; Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.

J Pharm Biomed Anal ; 215: 114776, 2022 Jun 05.

Article em En | MEDLINE | ID: mdl-35462286

Assuntos

Antituberculosos; Isoniazida; Antituberculosos/farmacocinética; Cromatografia Líquida/métodos; Monitoramento de Medicamentos/métodos; Humanos; Rifampina; Espectrometria de Massas em Tandem/métodos

Palavras-chave

Acetylisoniazid; Antituberculosis drugs; Bedaquiline; Liquid chromatography-tandem mass spectrometry; Multi-drug resistant tuberculosis; Rifampicin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isoniazida / Antituberculosos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isoniazida / Antituberculosos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article